Stratatech Announces Impressive Clinical Results for StrataGraft® Skin Tissue
1/16/2013 9:34:53 AM
MADISON, Wis.--(BUSINESS WIRE)--Stratatech Corp., a leader in regenerative medicine, today announced top-line results from its proof-of-concept clinical trial of StrataGraft®, a universal human skin substitute being developed for the treatment of severe burns. Enrollment of all 20 subjects is now complete and 19 of 20 patients avoided the need for painful autograft surgery and regrafting at their StrataGraft-treated sites. The one subject regrafted by day 28, a primary endpoint, also experienced graft failure at the control autograft site and other non-study sites. Seventeen of the remaining 19 evaluable subjects progressed to complete wound closure by 3 months, the trial’s second primary endpoint; one subject achieved closure after 3 months due to a wound dressing error that temporarily reopened her closed wound which had been 95% closed at 2 months; and wound healing in another subject continues to progress slowly but has not yet reached closure.